Business Description
China SXT Pharmaceuticals Inc
ISIN : VGG2161P1403
Share Class Description:
STU:2RY1: Ordinary Shares - Class ATotal Employee Number:
75Description
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly TCMP (Directed-oral TCMP and After-soaking TCMP), which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 25.14 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.19 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 10.74 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 91.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 100 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.94 | |||||
Quick Ratio | 7.76 | |||||
Cash Ratio | 6.48 | |||||
Days Inventory | 322.44 | |||||
Days Sales Outstanding | 381.57 | |||||
Days Payable | 299.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -14.78 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 21.88 | |||||
Operating Margin % | -625.92 | |||||
Net Margin % | -545.26 | |||||
EBITDA Margin % | -527.15 | |||||
FCF Margin % | -353.79 | |||||
OCF Margin % | -353.79 | |||||
ROE % | -28.47 | |||||
ROA % | -22.49 | |||||
ROIC % | -269.27 | |||||
3-Year ROIIC % | 13.98 | |||||
ROC (Joel Greenblatt) % | -1835.26 | |||||
ROCE % | -27.73 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 3 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.52 | |||||
PB Ratio | 0.08 | |||||
Price-to-Tangible-Book | 0.08 | |||||
EV-to-EBIT | -11.52 | |||||
EV-to-EBITDA | -11.8 | |||||
EV-to-Revenue | 62.2 | |||||
EV-to-FCF | -17.62 | |||||
Price-to-GF-Value | 1.25 | |||||
Price-to-Projected-FCF | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 0.08 | |||||
| Price-to-Net-Cash | 0.11 | |||||
Earnings Yield (Greenblatt) % | -8.68 | |||||
FCF Yield % | -4.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
China SXT Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.976 | ||
| EPS (TTM) (€) | -7.668 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 4.57 | ||
| Volatility % | 56.41 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 384 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 383.999998 - 384 | ||
| Shares Outstanding (Mil) | 0.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
China SXT Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
China SXT Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-07-31 | In 17 days | ||
| Annual report for 2026 | 2026-07-01 | 384.00 (+0.00%) | ||
| 0.00666667:1 Stock Split | 2026-02-03 | 384.00 (+0.00%) | ||
| Annual report for 2025 | 2025-07-31 | 384.00 (+0.00%) | ||
| 0.125:1 Stock Split | 2025-02-25 | 384.00 (+0.00%) | ||
| Annual report for 2024 | 2024-08-13 | 1,092.00 (+4.60%) | ||
| 0.04:1 Stock Split | 2023-10-05 | 3,510.00 (+6.56%) | ||
| 0.05:1 Stock Split | 2022-05-20 | 61,798.76 (+0.00%) | ||
| 0.25:1 Stock Split | 2021-02-22 | -- |
Show
Entries
China SXT Pharmaceuticals Inc Frequently Asked Questions
What is China SXT Pharmaceuticals Inc(STU:2RY1)'s stock price today?
The current price of STU:2RY1 is €384.00. The 52 week high of STU:2RY1 is €384.00 and 52 week low is €384.00.
When is next earnings date of China SXT Pharmaceuticals Inc(STU:2RY1)?
The next earnings date of China SXT Pharmaceuticals Inc(STU:2RY1) is .
Does China SXT Pharmaceuticals Inc(STU:2RY1) pay dividends? If so, how much?
China SXT Pharmaceuticals Inc(STU:2RY1) does not pay dividend.
Press Release
Articles on China SXT Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers